SCHEMBL3705487

SCHEMBL3705487

O=S(=O)(c1sccc1-c1cccnc1F)n1cccc1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSD P07339 1/20 0.31
BACE1 P56817 1/20 0.31
BACE2 Q9Y5Z0 1/20 0.31
EDNRA P25101 1/20 0.31
CA1 P00915 1/20 0.30
CA2 P00918 1/20 0.30
NAPRT Q6XQN6 1/20 0.30
GRIA2 P42262 2/20 0.30
KCNH2 Q12809 1/20 0.30
TDP2 O95551 1/20 0.30
NSD2 O96028 1/20 0.30
ABL1 P00519 1/20 0.30
PLCG1 P19174 1/20 0.30
CES1 P23141 1/20 0.30
PAX8 Q06710 1/20 0.30
RIN1 Q13671 1/20 0.30
MEN1 O00255 1/20 0.30
THRB P10828 1/20 0.30
BLM P54132 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3700772 0.77 CYP2A6 (0.39) CA1CA2GRIA2CYP2C19
SCHEMBL3697389 0.66 CA1 (0.39) CA1CA2
SCHEMBL7344928 0.66 CA1 (0.39) CA1CA2
SCHEMBL6970430 0.63 CA1 (0.40) CA1CA2MEN1KMT2A
SCHEMBL7637091 0.61 POLB (0.36) NAPRT
SCHEMBL28965976 0.61 CA1 (0.42) CA1CA2CYP2C19
SCHEMBL25317209 0.59 PKM (0.44) CA1CA2MEN1THRBKMT2A
SCHEMBL3655764 0.59 CYP2A6 (0.39) MEN1KMT2A
SCHEMBL16432358 0.59 NAPRT (0.43) NAPRTTDP2NSD2ABL1PLCG1
SCHEMBL29890083 0.59 NAPRT (0.43) NAPRTTDP2NSD2ABL1PLCG1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2190822-B1 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2014-12-31 EP disclosed
EP-2190822-A2 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2010-06-02 EP disclosed
WO-2009041705-A9 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2009-08-13 WO disclosed
US-20090156642-A1 5-Membered heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed
WO-2009041705-A2 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156642-A1 5-Membered heterocyclic compound CEL, PGA5, COG5 CTSD 264/4885BACE1 1566/4885BACE2 1053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.